Nanogen Issued Patent for Addressable Biologic Electrode Arrays
"Customers using biomedical diagnostic applications -- and ultimately the patients they serve -- will require increasingly sophisticated capabilities at reasonable cost," said Howard Birndorf, Nanogen chairman and chief executive officer. "Application of the technology described in this patent allows for continually increasing array densities and capabilities, which simultaneously would reduce both array cost and instrument size."
"One of the challenges in producing biologic arrays of increasing density is the integration of electronic control circuitry with each electrode on the array. The new patent describes a semiconductor-based switching technology that helps solve these scaling issues," said Dr. Michael J. Heller, co-founder of Nanogen, and currently a professor in the Departments of Bioengineering and Electrical and Computer Engineering at the University of California, San Diego.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.